| Asthma
Advair Diskus vs Xolair
Side-by-side clinical, coverage, and cost comparison for asthma.Deep comparison between: Advair vs Xolair with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXolair has a higher rate of injection site reactions vs Advair based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xolair but not Advair, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Advair
Xolair
At A Glance
Oral inhalation
Twice daily
ICS/LABA combination
SC injection
Every 2-4 weeks
Anti-IgE antibody
Indications
- Asthma
- Chronic Obstructive Airway Disease
- Asthma
- Chronic rhinosinusitis with multiple nasal polyps
- IgE-mediated food allergy
- Chronic Spontaneous Urticaria
Dosing
Asthma 1 inhalation twice daily approximately 12 hours apart; adults and adolescents aged >=12 years may use 100/50, 250/50, or 500/50 strengths (max ADVAIR DISKUS 500/50 twice daily); pediatric patients aged 4 to 11 years use 1 inhalation of ADVAIR DISKUS 100/50 twice daily.
Chronic Obstructive Airway Disease 1 inhalation of ADVAIR DISKUS 250/50 twice daily approximately 12 hours apart.
Asthma 75 to 375 mg SC every 2 or 4 weeks based on serum total IgE level (IU/mL) measured before the start of treatment and body weight (kg).
Chronic rhinosinusitis with multiple nasal polyps 75 to 600 mg SC every 2 or 4 weeks based on serum total IgE level (IU/mL) measured before the start of treatment and body weight (kg).
IgE-mediated food allergy 75 to 600 mg SC every 2 or 4 weeks based on serum total IgE level (IU/mL) measured before the start of treatment and body weight (kg).
Chronic Spontaneous Urticaria 150 or 300 mg SC every 4 weeks; dosing is not dependent on serum IgE level or body weight.
Contraindications
- Primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required
- Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone propionate, salmeterol, or any of the excipients
- Severe hypersensitivity reaction to omalizumab or any ingredient of XOLAIR
Adverse Reactions
Most common (>=3%) Upper respiratory tract infection, pharyngitis, headaches, candidiasis mouth/throat, throat irritation, hoarseness/dysphonia, musculoskeletal pain, viral respiratory infections, nausea and vomiting, bronchitis, sinusitis, dizziness, muscle cramps and spasms
Serious Serious asthma-related events (hospitalizations, intubations, death), pneumonia in patients with COPD, cardiovascular and CNS effects, Candida albicans infection, immunosuppression, hypercorticism and adrenal suppression, reduction in bone mineral density, growth effects in pediatric patients, glaucoma and cataracts
Postmarketing Arrhythmias (including atrial fibrillation, supraventricular tachycardia, ventricular tachycardia), Cushing's syndrome, glaucoma, hyperglycemia, osteoporosis, paradoxical bronchospasm, immediate and delayed hypersensitivity reactions including anaphylaxis, agitation, depression, dysmenorrhea
Most common (>=1%) Arthralgia, pain, injection site reactions, headache, fatigue, dizziness, pruritus, nasopharyngitis, sinusitis, upper respiratory tract infection, dermatitis, earache
Serious Anaphylaxis, malignancies, cardiovascular and cerebrovascular events
Postmarketing Anaphylaxis, eosinophilic conditions, fever with arthralgia and rash (serum sickness-like), severe thrombocytopenia, hair loss
Pharmacology
ADVAIR DISKUS combines fluticasone propionate, a synthetic trifluorinated corticosteroid that suppresses airway inflammation by acting on multiple cell types and mediators, and salmeterol, a selective long-acting beta2-adrenergic agonist (LABA) that relaxes bronchial smooth muscle by stimulating intracellular adenyl cyclase, increasing cyclic AMP levels.
Omalizumab is a recombinant humanized IgG1 monoclonal antibody that inhibits the binding of IgE to high-affinity IgE receptors (FceRI) on mast cells, basophils, and dendritic cells, resulting in FceRI down-regulation and reduction of IgE-mediated inflammatory responses; in CSU, omalizumab binds to IgE and lowers free IgE levels with down-regulation of IgE receptors, though the exact mechanism by which this results in CSU symptom improvement is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Advair
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (10/12)
Xolair
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (11/12) · Qty limit (11/12)
UnitedHealthcare
Advair
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Xolair
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (6/8)
Humana
Advair
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (3/3)
Xolair
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Advair.
Cost estimate not availableAccessia Health: Asthma - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AdvairView full Advair profile
XolairView full Xolair profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.